On June 6, 2022 Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, reported an expansion of its product roadmap and the availability of the Formalin-Fixed Paraffin-Embedded (FFPE) Human Immuno-oncology data release (Press release, Vizgen, JUN 6, 2022, View Source [SID1234615646]). Vizgen’s product updates will expand sample input flexibility, propel new applications, and empower greater data insights. These updates demonstrate the company’s continued commitment to exposing the research community to the power of spatial genomics. The updates will be presented as oral and poster presentations at the Advances in Genome Biology and Technology (AGBT) 2022 General Meeting, occurring June 6-9, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Product roadmap updates for 2H 2022:

Formalin-Fixed Paraffin-Embedded Sample Preparation Solution enabling MERFISH measurements on FFPE tissue samples.
Protein Co-detection Kit for the simultaneous detection of RNA and proteins during a standard MERFISH experiment, enabling multi-omics measurements.
1,000 Plex Gene Panels for the detection of up to 1,000 gene targets within a single MERFISH experiment, resulting in higher gene target coverage which is crucial when performing initial discovery experiments.
The new publicly available FFPE Human Immuno-oncology dataset, generated with Vizgen’s MERSCOPE platform, represents the largest public data set for single-cell spatial genomics ever released. This data was generated using Vizgen’s forthcoming FFPE Sample Preparation Kit. The dataset contains 16 total datasets from 8 FFPE tumor tissue types including breast, colon, lung, liver, skin, prostate, uterine and ovarian, each measuring 500 genes totaling over 4 billion transcripts and 9 million cells cumulatively. The dataset is freely available to participants in the company’s Data Release Program to use in any way and can be downloaded at View Source

"We announced MERSCOPE, the industry’s first solution to combine single-cell and spatial transcriptomics in one turnkey system, and the only commercial platform solution for MERFISH technology, last year at AGBT. Customer adoption from academic research institutions and pharmaceutical companies has been tremendous and our platform continues to lead spatial genomics innovation in the industry," said Terry Lo, President and CEO of Vizgen. "With this first of its kind data release, the research community now has access to an unprecedented scale and quality of single-cell spatial genomics data from cancer samples. As we look to establish new standards in the field, we are excited about our upcoming roadmap of new capabilities that further our mission to improve human health."

For additional information about Vizgen’s Human FFPE Immuno-oncology Data Release, visit: View Source